Ligand Pharmaceuticals LGND Payments To Acquire Financial Royalty Assets
Payments To Acquire Financial Royalty Assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:PaymentsToAcquireFinancialRoyaltyAssets.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's payments to acquire financial royalty assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's payments to acquire financial royalty assets?
- Ligand Pharmaceuticals (LGND) reported payments to acquire financial royalty assets of $0 in Q1 2026.
- How has Ligand Pharmaceuticals's payments to acquire financial royalty assets changed year-over-year?
- Ligand Pharmaceuticals's payments to acquire financial royalty assets decreased by 100.0% year-over-year, from $1.82M to $0.
- What does payments to acquire financial royalty assets mean?
- This represents the cash outflow dedicated to the acquisition of new financial royalty streams or rights to future revenue from third-party products. It is a primary indicator of the company's capital allocation strategy toward expanding its royalty-based business model. High levels of investment here suggest a focus on long-term growth through the accumulation of diversified revenue-generating assets.